Aquestive plans 75-rep Anaphylm launch and targets $46M–$50M in 2026 revenue while doubling medical affairs (NASDAQ:AQST)

Management View - Aquestive Therapeutics is optimistic about its future, with CEO Daniel Barber stating that the company's path has never been clearer [2] - The company plans to launch a 75-rep Anaphylm and targets revenue between $46 million and $50 million in 2026 [2] - There is a commitment to doubling the medical affairs team to support growth initiatives [2]